Share chart Black Diamond Therapeutics, Inc.
Extended chart
Simple chart
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., биотехнологическая компания, обнаруживает и разрабатывает маломолекулярные методы лечения опухолей. Его основным кандидатом в продукт является BDTX-189, необратимый низкомолекулярный ингибитор, который предназначен для блокирования функции семейства онкогенных белков, определяемых мутациями драйверов в ряде типов опухолей, и которые влияют на рецептор эпидермального фактора роста (EGFR), тирозин-протеинкиназа или рецептор 2 эпидермального фактора роста человека. more details| IPO date | 2020-01-30 |
|---|---|
| ISIN | US09203E1055 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | http://www.blackdiamondtherapeutics.com |
| Цена ао | 1.68 |
| Change price per day: | -6.15% (1.79) |
|---|---|
| Change price per week: | -11.58% (1.9) |
| Change price per month: | -22.94% (2.18) |
| Change price per 3 month: | -32.8% (2.5) |
| Change price per half year: | -72.86% (6.19) |
| Change price per year: | -63% (4.54) |
| Change price per 3 year: | -52.81% (3.56) |
| Change price per 5 year: | -93.78% (26.99) |
| Change price per 10 year: | 0% (1.68) |
| Change price per year to date: | -23.29% (2.19) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Bellevue Group AG | 8535839 | 16.5 |
| NEA Management Company, LLC | 4448757 | 8.6 |
| T. Rowe Price Investment Management, Inc. | 3927879 | 7.59 |
| RA Capital Management, L.P. | 3525754 | 6.82 |
| Artal Group S.A. | 2046517 | 3.96 |
| Vanguard Group Inc | 1947093 | 3.76 |
| Tang Capital Management, LLC | 1803200 | 3.49 |
| Verition Fund Management, LLC | 1554629 | 3.01 |
| Blackrock Inc. | 1350047 | 2.61 |
| JP Morgan Chase & Company | 821634 | 1.59 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Invesco Dorsey Wright SmallCap Momentum ETF | 0.33152 | 33.91 | 0.61241 |
| iShares Micro-Cap ETF | 0.04806 | 17.09 | 1.54048 |
| Vanguard Russell 2000 ETF | 0.01 | 17.16 | 1.48801 |
| Vanguard Russell 2000 Growth ETF | 0.01 | 23.05 | 0.60264 |
iShares Russell 2000 Growth ETF
|
0.00994 | 38.04 | 0.6026 |
ProShares UltraPro Russell2000
|
0.00382 | 89.82 | 1.47873 |
| ProShares Hedge Replication ETF | 0.00107 | 5.92 | 1.47892 |
| Dimensional U.S. Targeted Value ETF | 0.00076 | 26.01 | 1.93487 |
| Dimensional U.S. Core Equity 2 ETF | 0.00043 | 30.76 | 1.47098 |
| Dimensional US Core Equity Market ETF | 0.00024 | 30.98 | 1.40618 |
| Dimensional U.S. Equity ETF | 0.00003 | 31.53 | 1.3557 |
| Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
| 0.03 | 31.34 | 1.28 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Brent Hatzis-Schoch Esq., J.D. | COO & General Counsel | 683.29k | 1965 (60 years) |
| Dr. Elizabeth Buck Ph.D. | Co-Founder & Chief Scientific Officer | 340.47k | 1975 (50 years) |
| Dr. David M. Epstein Ph.D. | Co-Founder & Director | 885.08k | 1959 (66 years) |
| Dr. Fang Ni Pharm.D. | CFO, Principal Financial Officer and Chief Business Officer | 656.33k | 1987 (38 years) |
| Ms. Erika Jones | Senior VP of Finance & Corporate Controller | N/A | 1985 (40 years) |
| Ms. Elizabeth L. Montgomery | Chief People Officer | N/A | 1972 (53 years) |
| Dr. Sergey Yurasov M.D., Ph.D. | Chief Medical Officer | N/A | 1969 (56 years) |
| Ms. Melanie Morrison | Chief Development Officer | N/A | 1975 (50 years) |
| Dr. Mark A. Velleca M.D., Ph.D. | CEO, President & Chairman | 43.89k | 1964 (61 year) |
Address: United States, Cambridge, MA , One Main Street - open in Google maps, open in Yandex maps
Website: http://www.blackdiamondtherapeutics.com
Website: http://www.blackdiamondtherapeutics.com
